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ABSTRACT
Background
Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and
the United States by travelers on commercial airlines from Africa underscores the public health
challenge of emerging viruses. Currently, there are no licensed vaccines for Lassa fever, and no
experimental vaccine has completely protected nonhuman primates against a lethal challenge.
Methods and Findings
We developed a replication-competent vaccine against Lassa virus based on attenuated
recombinant vesicular stomatitis virus vectors expressing the Lassa viral glycoprotein. A single
intramuscular vaccination of the Lassa vaccine elicited a protective immune response in
nonhuman primates against a lethal Lassa virus challenge. Vaccine shedding was not detected
in the monkeys, and none of the animals developed fever or other symptoms of illness
associated with vaccination. The Lassa vaccine induced strong humoral and cellular immune
responses in the four vaccinated and challenged monkeys. Despite a transient Lassa viremia in
vaccinated animals 7 d after challenge, the vaccinated animals showed no evidence of clinical
disease. In contrast, the two control animals developed severe symptoms including rashes,
facial edema, and elevated liver enzymes, and ultimately succumbed to the Lassa infection.
Conclusion
Our data suggest that the Lassa vaccine candidate based on recombinant vesicular stomatitis
virus is safe and highly efficacious in a relevant animal model that faithfully reproduces human
disease.
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Among the viruses causing severe hemorrhagic fever in
Africa, Lassa fever is a signiﬁcant public health problem in
Nigeria, Liberia, Sierra Leone, and the Republic of Guinea. It
is estimated that Lassa virus infects over 200,000 individuals
per year across this region, causing over 3,000 deaths [1]. The
case fatality rate for Lassa fever is around 15% in hospitalized
patients and has been greater than 50% in several outbreaks
[2,3]. Human infection is associated with contact with a
widely distributed and highly commensal rodent, Mastomys
natalensis, or by contact with infected patients. Recent
importation of Lassa fever into Germany, the Netherlands,
the United Kingdom, and the United States by travelers on
commercial airlines [4–8] illustrates the potential for the
spread of this highly dangerous and contagious pathogen. In
addition, Lassa virus has gained notoriety because it is
classiﬁed as a Category A bioweapon agent [9].
Lassa virus is an enveloped, bisegmented RNA virus
belonging to the Old World group within the family
Arenaviridae [10]. Arenavirus particles contain a genome
consisting of two ambisense single-stranded RNA molecules,
designated small (S) and large (L), of a length about 3.4 kb and
7.2 kb, respectively. The S segment contains two genes that
encode three structural proteins, the nucleoprotein (NP) and
the envelope glycoproteins GP1 and GP2. The L segment
contains two genes that encode two proteins, the viral
polymerase (L protein) and the Z protein. NP and L protein
associate with the genomic RNA in a ribonucleoprotein
complex or nucleocapsid structure. It is thought that the Z
protein functions as a matrix protein and is responsible for
the formation of virus particles [11]. GP1 and GP2 are initially
synthesized as a precursor molecule, glycoprotein C (GPC),
which is posttranslationally cleaved by the protease SKI-1/S1P
[12]. GP1 is the portion of the surface glycoprotein spike that
is thought to be the effector for receptor binding, while GP2
is structurally consistent with viral transmembrane fusion
proteins of other enveloped viruses [13].
Currently, there are no vaccines or antiviral drugs approved
for Lassa fever. Treatment with intravenous ribavirin was
shown to reduce mortality from Lassa fever in high-risk
patients and presumably decreases morbidity in all patients
with Lassa fever [14]. However, the availability of ribavirin is
verylimitedinendemicareas,andtreatmentismosteffectiveif
initiated within the ﬁrst week of disease onset [14]. Preventing
contact with the reservoir host in endemic areas is currently
unachievable;therefore,apreventivevaccineisacriticalpublic
health need, especially to protect health care providers, who
are often the most at risk. Indeed, the recent untimely death of
a well-known doctor in Sierra Leone who treated thousands of
cases of Lassa fever and ultimately contracted the disease as a
result of these laudable efforts [15] underscores the need for a
preventive vaccine.
Early attempts to develop a vaccine against Lassa fever
focused on classical approaches such as killed vaccines. A
whole-virion vaccine inactivated by gamma irradiation pro-
videdagood humoralresponse toLassaviralproteins,NP,and
GP, but failed to protect nonhuman primates from a lethal
Lassachallenge[16].Astheseanimalswereunprotecteddespite
a strong humoral response, it was suggested that protection
would depend on a robust cellular response. Subsequent
efforts to develop an efﬁcacious vaccine against Lassa fever
focused on genetically engineered vaccines. Speciﬁcally,
studies focused on recombinant vaccinia viruses expressing
theNP,thefull-lengthGPC,andcombinationsofGP1andGP2.
In a series of studies by Fisher-Hoch and colleagues, approx-
imately 90% of nonhuman primates that received a vaccine
containing bothGP1 andGP2 surviveda lethal Lassachallenge
[1,17,18].Protectiondidnotcorrelatewithhumoralimmunity,
asnone of theseanimals had demonstrable Lassa virus-speciﬁc
antibody before challenge. Consequently, cell-mediated im-
munitywasimplicatedinprotectingtheseanimals,althoughT-
cell responses were not measured in these studies. In
comparison, vaccination of macaques with NP alone resulted
in the development of relatively high antibody titers before
Lassa challenge, but only 20% survival.
While the recombinant vaccinia vaccines expressing the
full-length Lassa GPC protected nearly 90% of nonhuman
primates from a lethal challenge, it was noted that the
vaccinia platform is not suitable for human use because of
potential side effects, which is a particular concern in areas
where HIV prevalence is high [1]. However, it appears from
all previous studies that a strong cellular response may be
required for protection. Vaccination with a live virus
characteristically elicits strong cellular immune responses,
and live vaccines are particularly attractive because they can
confer protection in a single injection. Therefore, the ideal
Lassa vaccine would be based on a replication-competent
format engineered for enhanced safety and with the ability to
overcome technical obstacles such as prior immunity to the
vector. Recently, we described the generation of a live
attenuated, recombinant vesicular stomatitis virus (rVSV)
expressing the GPC of Lassa virus, strain Josiah [19]. Vaccines
based on live attenuated rVSV have been highly effective in
animal models and are particularly attractive because they
can be administered by the mucosal route [20–23]. Further-
more, vesicular stomatitis virus (VSV) infections in humans
occur fairly rarely worldwide, mainly in the enzootic regions
of the Americas, and consequently, global pre-existing
immunity is negligible [24]. Because the guinea pig model
of Lassa fever does not faithfully mimic human disease [25]
and is not generally predictive for efﬁcacy of vaccines and
antivirals [1], we evaluated the protective efﬁcacy of the
replicating rVSV vector in nonhuman primates.
Methods
Vaccine Vectors and Viruses
The recombinant VSV expressing the glycoprotein of Lassa
virus, strain Josiah, and Zaire ebolavirus (ZEBOV), strain
Mayinga, were generated as described recently using the
infectiousclonefortheVSV,Indianaserotype(kindlyprovided
byJohnRose,YaleUniversity,NewHaven,Connecticut,United
States) [19]. Brieﬂy, the appropriate open reading frames for
the glycoproteins were generated by PCR, cloned into the VSV
genomic vectors lacking the VSV glycoprotein gene, se-
quenced-conﬁrmed, and rescued using the method described
earlier [26]. The recombinant viruses expressing Lassa virus
glycoprotein and ZEBOV glycoprotein were designated
VSVDG/LVGPC (Figure 1A) and VSVDG/ZEBOVGP, respec-
tively. Cynomolgus macaques were challenged with Lassa virus
isolated from a human case in 1976 in Sierra Leone [27].
Animal Studies
Six cynomolgus macaques (Macaca fascicularis), 4–6 y old and
weighing between 3 kg and 8 kg, were obtained from
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intramuscularly with approximately 2 3 10
7 PFU of VSVDG/
LVGPC, and two with an equivalent dose of VSVDG/ZEBOGP
(controls). The six cynomolgus macaques were challenged
intramuscularly 28 d after the single-dose immunization with
1 3 10
4 plaque-forming units (PFU) of Lassa virus, Josiah
strain. Animals were closely observed twice daily after the
immunization and the challenge for clinical symptoms. Swab
samples (oral, nasal, rectal, vaginal) and blood were collected
as shown in Figure 1B. Studies were performed in biosafety
level (BSL)-4 biocontainment. Research was conducted in
compliance with the Animal Welfare Act and other federal
statues and regulations relating to animals and experiments
involving animals, and adheres to the National Research
Council laboratory animal care principles [28]. The facility
used is fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
Hematology and Serum Biochemistry
Total white blood cell counts, white blood cell differentials,
red blood cell counts, platelet counts, hematocrit values, total
hemoglobin, mean cell volume, mean corpuscular volume,
and mean corpuscular hemoglobin concentration were
determined from blood samples collected in tubes containing
EDTA, by using a laser-based hematologic analyzer (Coulter
Electronics, Hialeah, Florida, United States). The white blood
cell differentials were performed manually on Wright-stained
blood smears. Serum samples were tested for concentrations
of albumin (ALB), amylase, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase
(ALP), gamma-glutamyltransferase (GGT), glucose, cholester-
ol, total protein, total bilirubin (TBIL), urea nitrogen (BUN),
and creatinine (CRE) by using a Piccolo Point-Of-Care Blood
Analyzer (Abaxis, Sunnyvale, California, United States).
Virus Detection
RNA was isolated from blood and swabs using the appro-
priate RNA isolation kits from QIAGEN (Mississauga, Ontario,
Canada).TodetectVSVweusedanRT-PCRassaytargetingthe
matrix gene. Lassa viral RNA was detected using a primer pair
targeting the gene encoding L protein. Virus was titrated by
plaque assay on Vero E6 cells from all blood and selected and
swab samples and from tissue samples collected at necropsy
(liver, spleen, lung, kidney, adrenal gland, pancreas, lymph
nodes, bone marrow, ovary, testis, and brain) [29].
Humoral Immune Responses
IgG antibodies against Lassa virus were detected with an
ELISA using puriﬁed viral particles as an antigen source [30].
Neutralization assays were performed by measuring plaque
reduction in a constant virus:serum dilution format as
previously described [29]. Brieﬂy, a standard amount of Lassa
virus (approximately 100 PFU) was incubated with serial 2-
fold dilutions of the serum sample for 60 min. The mixture
was used to inoculate Vero E6 cells for 60 min. Cells were
overlaid with an agar medium and incubated for 8 d. Plaques
were counted 48 h after neutral red staining. Endpoint titers
were determined by the dilution of serum which neutralized
50% of the plaques.
Cellular Immune Responses
Peripheral blood mononuclear cells (PBMCs) were isolated
by histopaque gradient (Sigma, St. Louis, Missouri, United
States) from each animal before vaccination and transformed
with Herpesvirus papio to serve as antigen-presenting cells.
Each day on which assays were performed, 5 3 10
5 trans-
formed cells from each animal were dispensed and infected
with VSVDG/LVGPC at a multiplicity of infection of 1.0. At 12
h postinfection, transformed cells from each animal were
individually mixed with PBMCs collected from the respective
animals. For example, transformed cells from subject 1 were
mixed with PBMCs collected from subject 1. Anti-CD28 and
anti-CD49d antibodies (1.0 lg of each antibody; BD Phar-
mingen, San Diego, California, United States) and GolgiPlug
(BD Pharmingen) were added to each coculture and
incubated for 6 h at 37 8C. Staphylococcal enterotoxin B
was added as a positive control to one set of cultures. Cultures
were placed at 4 8C overnight. Cocultured cells were stained
for CD8, CD3, and CD4 in Pharmingen stain buffer (BD
Pharmingen) for 20 min at 4 8C in the dark. Cells were washed
with Pharmingen stain buffer and ﬁxed/permeabilized with
Cytoﬁx/Cytoperm buffer (BD Pharmingen) for 1–1.5 h in the
dark at 4 8C. Cells were then washed in 13Perm/Wash buffer
(BD Pharmingen) and stained with interferon gamma (IFN-c)-
allophycocyanin or tumor necrosis factor alpha (TNF-a)-
allophycocyanin in 13Perm/Wash buffer for 45 min at 4 8Ci n
the dark. Cells were next washed in 13Perm/Wash buffer and
resuspended in Cytoﬁx/Cytoperm buffer for analysis. Acquis-
ition was performed on a FACS Calibur ﬂow cytometer
Figure 1. Lassa Virus Vaccine Design and Vaccination Regimen
(A) Left, schematic diagram of the recombinant VSV expressing the
glycoprotein of Lassa virus. The VSV glycoprotein (G) was replaced
with the Lassa virus glycoprotein (LV GPC). Shown are the
nucleocapsid (N), phosphoprotein (P), matrix (M), and RNA-depend-
ent RNA polymerase (L). Right, gold sphere labeling (10-nm spheres)
of VSVDG/LVGPC particles by immunoelectron microscopy using a
pool of two murine monoclonal antibodies directed against Lassa
virus GP1 and GP2; particles were negatively contrasted with 1%
uranyl acetate.
(B) Time line for vaccination and Lassa viral challenge study.
Vaccination of cynomolgus monkeys was done with a single intra-
muscular dose of 10
7 PFU of either VSVDG/LVGPC (four animals) or
VSVDG/ZEBOVGP (two animals). Challenge was performed with a
single intramuscular dose of 10
4 PFU of Lassa virus, strain Josiah.
Arrows indicate day of sampling (blood and swabs).
DOI: 10.1371/journal.pmed.0020183.g001
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sample, and analyzed using FloJo software (Tree Star,
Ashland, Oregon, United States). Cytokine-positive cells were
deﬁned as a percentage of double-positive cells for CD8 and
CD4 populations within the lymphocyte gate.
Statistics
Vaccine efﬁcacy was calculated using Fisher’s exact test. A
p-value of 0.05 or lower was considered signiﬁcant.
Results
Protection against Lassa Fever
We tested the Lassa fever rVSV vaccine candidate in
nonhuman primates. Four cynomolgus macaques (M. fascicu-
laris) were immunized by intramuscular injection with a single
dose of approximately 2 3 10
7 PFU of VSVDG/LVGPC, and
two control animals received VSVDG/ZEBOVGP (same route
and dose). The animals were monitored closely for clinical
symptoms and shedding of rVSVs. Figure 1B shows the
inoculation and sampling protocol that was followed for this
study. After vaccination, none of the nonhuman primates
displayed any signs of clinical symptoms, indicating that the
rVSVs were apathogenic for these animals. All six animals
were subsequently challenged intramuscularly on day 28
postvaccination with a high dose (1310
4 PFU) of Lassa virus.
The two control animals (vaccinated with irrelevant VSVDG/
ZEBOVGP) started to show clinical signs of illness on day 3,
when one of the animals had a fever (deﬁned as a temper-
ature over 104 8F). By day 10, both control animals developed
macular rashes and anorexia, and one animal had severe
facial edema, which is prognostic for a poor outcome in
humans [31]. These control animals succumbed to the Lassa
virus challenge and were euthanized on day 11 and day 13,
respectively. At necropsy, both controls showed lesions and
pathological changes consistent with Lassa fever in nonhu-
man primates [25,32]. In contrast, none of the VSVDG/
LVGPC-vaccinated animals became sick, and all four animals
were fully protected against the high Lassa challenge dose.
Survival was statistically signiﬁcant (p = 0.0079 by Fisher’s
exact test) when the four VSVDG/LVGPC-vaccinated mac-
aques were compared to the two nonspeciﬁcally vaccinated
animals and three recent controls that succumbed to a Lassa
challenge using the same dose of the same virus isolate
delivered by the same route (T. W. G., unpublished data).
Analysis of blood chemistry and hematology was performed
on the indicated days (Figure 1B; Table 1); values in the
VSVDG/LVGPC-vaccinated animals did not differ signiﬁ-
cantly from pre-challenge values. There were slight pertur-
bations in platelet counts at day 7 after Lassa challenge in
three of the four VSVDG/LVGPC-vaccinated animals, with a
small decrease in platelet numbers. This modest drop in
platelets was also noted in one of the two VSVDG/ZEBOVGP-
vaccinated control animals at day 7. In addition, a marked
lymphopenia developed in both control animals, but was not
observed in any of the four VSVDG/LVGPC-vaccinated
macaques. Signiﬁcant changes in clinical chemistry (greater
than 3-fold changes from baseline values) were seen in both
control animals in ALT and AST (Figure 2). In addition,
increases were also seen in serum levels of ALP, GGT, TBIL,
and BUN, while decreased levels of ALB and CRE were
evident in one of these animals. The only perturbation in
clinical chemistry values among the four VSVDG/LVGPC-
vaccinated animals was very slight increases in the ALT levels
in two of the animals at day 7 and a third monkey at day 10.
No Viremia or Shedding of Vaccine Vector
To determine if viremia or shedding of the rVSVs occurs
after vaccination, whole blood and swab samples (oral, nasal,
vaginal, and rectal) from all six vaccinated animals were
analyzed by virus isolation and RT-PCR assay. A moderate
viremia was detected on day 2 postimmunization by virus
isolation (10
3–10
4 PFU/ml) and RT-PCR in the two VSVDG/
ZEBOVGP-vaccinated control animals, but viremia was not
detected at any time point in any of the four VSVDG/LVGPC-
vaccinatedmacaques(Figure3A).Noevidenceofsheddingwas
detected by virus isolation or RT-PCR in any of the swab
samplesfromanyofthesixanimalsevaluated.Thus,thereisno
evidence that virus could be shed under the conditions tested.
Vaccine Protects against Lassa Fever but Immunity Is Not
Sterile
Lassa viral replication and shedding was analyzed by virus
isolation and RT-PCR from the blood and swab samples taken
after Lassa challenge (see Figure 1B). Organ samples from the
two control animals (vaccinated with irrelevant VSVDG/
ZEBOVGP) were also available. At day 3 after Lassa challenge,
viremia was detected in one of the two control animals
(Figure 3B), but not in the second control animal or in any of
the four VSVDG/LVGPC-vaccinated monkeys. By day 7, all six
monkeys were viremic (viremia up to approximately 10
4 PFU/
ml) (Figure 3B). However by day 10, all four of the VSVDG/
LVGPC-vaccinated animals had cleared the viremia, while
both control animals had high viremias (more than 10
6 PFU/
ml), which was maintained until euthanasia. High levels of
Lassa virus were also detected in organ samples of these two
control animals (10
4–10
9 PFU/g) (unpublished data).
Strong Humoral and Cellular Immune Response after
Lassa Virus Challenge
By the day of Lassa challenge, all four VSVDG/LVGPC-
vaccinated monkeys had developed moderate- to high-level
IgG antibody titers (Figure 4A), with three of four animals
having titers over 1 in 800. In addition, all four VSVDG/
LVGPC-vaccinated monkeys developed low-level neutralizing
antibody titers against Lassa virus (Figure 4B). After Lassa
virus challenge, ELISA and neutralizing antibody titers
markedly increased in all four VSVDG/LVGPC-vaccinated
monkeys (Figure 4). The cellular immune response was
measured by intracellular cytokine staining for IFN-c and
TNF-a in CD4- and CD8-positive lymphocytes. Before Lassa
virus challenge, the production of IFN-c and TNF-a was
detectable in CD8-positive lymphocytes in one of four
VSVDG/LVGPC-vaccinated monkeys (subject 2). After Lassa
virus challenge, three of the four VSVDG/LVGPC-vaccinated
animals responded positively, with values between 0.15% to
0.93% positive IFN-c- or TNF-a-positive CD8 cells (Figures 5
and 6). Two of these three animals also ranged between 0.19%
and 0.36% positive IFN-c- or TNF-a-positive CD4 cells. These
results indicate that the VSVDG/LVGPC was a potent
stimulator of humoral and cellular immunity.
Discussion
The VSV-based vector expressing the Lassa virus GPC
mediated complete protection of four of four cynomolgus
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Protection was associated with the generation of Lassa-
speciﬁc CD8
þ T cell and antibody responses. Although the
presence of preexisting ELISA and neutralizing anti-GP
antibodies were associated with protection, previous studies
in nonhuman primates showed little to no anti-glycoprotein
antibodies after vaccination with vaccinia recombinants
expressing the full-length Lassa viral glycoprotein [18].
Notably, signiﬁcant increases in the levels of antibodies were
detected after the vaccinia-immunized macaques were chal-
lenged with infectious Lassa virus, but levels of neutralizing
antibodies were not observed before or after Lassa virus
challenge in these studies. Indeed, in the current study, we
also observed increased levels of antibodies in the VSVDG/
LVGPC-vaccinated animals after Lassa virus challenge,
including substantial increases in the levels of neutralizing
antibodies. While previous studies have implied that cellular
immunity is necessary for protection against Lassa fever, no
previous study to our knowledge has evaluated the cellular
immune response in nonhuman primates. Here, we show that
cytotoxic T lymphocytes appear to play an important role in
protection, as production of IFN-c and TNF-a was detected
in CD8-positive lymphocytes in three of the four VSVDG/
LVGPC-vaccinated macaques after Lassa challenge. However,
we cannot discount the importance of neutralizing antibodies
as another potential mechanism of protection.
In this study, protection against Lassa fever was dependent
on vaccination with an attenuated, replication-competent
virus, which may raise questions regarding the safety of live-
attenuated vectors. Most importantly, we demonstrated here
that, despite a short-term viremia in two animals immunized
with the control VSVDG/ZEBOVGP vaccine, rVSV replication
and shedding were not detectable in nonhuman primates,
and the animals did not develop fever or other symptoms, nor
were there changes in blood chemistry or hematology.
Increased concern about natural or artiﬁcial introductions
of emerging viruses such as Lassa virus has driven increased
investment in basic research and construction of a network of
biocontainment laboratories. In the past, a relatively small
global market and a lack of biocontainment facilities
generated little commercial interest for developing a Lassa
fever vaccine. Therefore, there have been relatively few
attempts to evaluate vaccines against Lassa fever in nonhu-
man primate models. It is difﬁcult to compare results across
these few studies because of a number of variables, including
differences among animal species and dose, route, and strain
of challenge virus employed. It is important to note that two
different species of nonhuman primates (M. fascicularis and M.
mulatta) were employed in the previous studies evaluating
vaccinia virus as a platform for a Lassa fever vaccine [1,17,18].
Those studies, which used seven cynomolgus monkeys, offer a
good comparison with the current study, as these animals
were immunized with a vaccinia construct expressing the
Lassa viral GPC and were challenged with 10
4 PFU of Lassa
virus (Josiah strain) [18]. Five of these seven vaccinia-Lassa
GPC-vaccinated cynomolgus monkeys were protected from a
lethal Lassa viral challenge, compared to the result of
protection of four of four cynomolgus monkeys from 10
4
PFU of Lassa virus (Josiah strain) in the current study.
Differences between these two vaccine platforms were also
noted in circulating Lassa viral loads and clinical illness.
While Lassa viremia was detected in both studies in all
vaccinated animals at postinfection day 7, we failed to detect
viremia in any VSVDG/LVGPC-vaccinated animal at day 10.
Table 1. Blood Chemistry and Hematology Results for Cynomolgus Monkeys before and after Challenge with Lassa Virus
Category Parameter VSVDG/LVGPC-Vaccinated Controls
Before LV After LV Before LV After LV
Biochemical ALB NC NC NC Modest #
Amylase NC NC NC NC
ALT NC Slight " NC Marked "
AST NC NC NC Marked "
ALP NC NC NC Modest "
CRE NC NC NC Modest #
GGT NC NC NC Modest "
Glucose NC NC NC NC
Cholesterol NC NC NC NC
Total protein NC NC NC NC
TBIL NC NC NC Modest "
BUN NC NC NC NC
Hematological Total white blood cells NC NC NC NC
Lymphocytes NC NC NC Marked #
Neutrophils NC NC NC Modest "
Red blood cells NC NC NC NC
Platelets NC Slight # NC Modest #
Hematocrit NC NC NC NC
Total hemoglobin NC NC NC NC
Mean cell volume NC NC NC NC
Mean corpuscular volume NC NC NC NC
Mean corpuscular hemoglobin NC NC NC NC
VSVDG/LVGPC-vaccinated, four cynomolgus macaques vaccinated with VSV expressing the Lassa virus glycoprotein; controls, two cynomolgus monkeys vaccinated with VSV expressing an irrelevant antigen; LV, Lassa virus; NC, no change
detected; ", increase in parameter; #, decrease in parameter.
DOI: 10.1371/journal.pmed.0020183.t001
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vaccinia virus platform, viremia was detected in four of the
seven vaccinated animals at day 10 [18]. Consistent with
differences in the duration of viremia, we failed to detect any
evidence of clinical illness in any of the four VSVDG/LVGPC-
vaccinated macaques after Lassa virus challenge, while a
transient febrile illness with moderate physiological changes
was reported in the vaccinia-Lassa GPC-vaccinated monkeys
after Lassa virus challenge [1]. All experimental controls died
in the current study and the previous studies [1,18]. The Lassa
viral challenge seed used in our study was uniformly lethal in
12 of 12 cynomolgus monkeys challenged by the same route
with a comparable dose [33] and three of three cynomolgus
monkeys with the exact same dose (T.W.G., unpublished data);
thus, protection of four of four VSVDG/LVGPC-vaccinated
monkeys is highly signiﬁcant (p = 0.0079).
It will be important to determine whether this rVSV
vaccine can protect against other strains of Lassa virus or
whether successful vaccination will require additional genes
to confer heterologous protection. Others have demonstrated
that vaccination of nonhuman primates with the nonpatho-
genic and closely related Mopeia virus protects animals from
a lethal Lassa virus (Josiah strain) challenge [17,18] suggesting
that broad protection is an attainable goal.
The potency of the immune responses induced in this study
led us to speculate that complete protection could be
achievable in less than the 28 d between immunization and
challenge, but this notion, of course, must be experimentally
tested. A shortened regimen would be a signiﬁcant advance in
the event of either a natural outbreak or bioterrorism, as
both occur rapidly with little warning and require swift and
effective measures to reduce their impact on risk groups such
as health-care and military personnel. An immediate
response is needed to contain an outbreak and prevent the
spread of disease to other geographic regions. So far,
quarantine practices appear to be effective in limiting Lassa
outbreaks, which have been most severe in rural hospitals
[2,3]. However, infection and mortality have been devastating
in the quarantined community [2,3], and modern advances in
global travel cannot ensure that future outbreaks will be as
easily contained. While rodent control would be an effective
way to greatly reduce the number of cases of Lassa fever in
West Africa, current economic barriers make such control
unlikely. Thus, the availability of a vaccine that could be
Figure 3. Viremia in Nonhuman Primates after Vaccination and Lassa
Virus Challenge
Viremia levels after vaccination (A) and Lassa virus challenge (B) were
determined in plasma taken at the indicated times after vaccination
and Lassa virus challenge (see Figure 1B). RNA was isolated from
plasma, and PCR speciﬁc for VSV and Lassa virus were performed as
described in Methods. Note: Subjects 1–4 were vaccinated with
VSVDG/LVGPC, while controls 1 and 2 were vaccinated with VSVDG/
ZEBOVGP.
DOI: 10.1371/journal.pmed.0020183.g003
Figure 2. Hepatic Enzyme Levels in Sera of Cynomolgus Monkeys After
Challenge with Lassa Virus
Results of ALT (A) and AST (B) assays are shown for the four VSVDG/
LVGPC-vaccinated macaques (closed symbols) and the two control
monkeys (open symbols).
DOI: 10.1371/journal.pmed.0020183.g002
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Vaccine against Lassa Feverrapidly employed to create a ring of vaccination around an
epidemic zone would be critical to controlling the subsequent
spread of Lassa virus. Here, our one-dose, 4-wk, rVSV-based
Lassa immunization regimen demonstrates the plausibility of
developing a candidate vaccine to meet this need.
The recent focus on development of vaccines against highly
pathogenic viruses has been concentrated on various re-
combinant vectors (e.g., adenoviruses, alphavirus replicons,
vaccinia, DNA vaccination) for expression of virus-encoded
proteins in various combinations to induce protective
immunity [29,34,35]. While many of these approaches show
promise, an important technical obstacle that is inherent with
most of these platforms is the potential for prior immunity to
the vector either through natural exposure or prior immu-
nization [36–38]. This is an area in which the rVSV platform
has a competitive advantage over many of the other formats.
Preexisting immunity in the human population against VSV
is minimal and may not be important at all, because
neutralizing antibodies are directed against the VSV glyco-
protein [21], which is not expressed using the recombinant
vector described here.
The primary concern regarding use of the rVSV vaccine
platform in humans is related to the fact that this is a
replication-competent vaccine, and thus demonstration of
safety is of paramount importance. Pathogenicity associated
with VSV and rVSVs is a concern that will require further
investigation. However, the VSV glycoprotein, which is
thought to be the main determinant of pathogenicity for
VSV, has been completely deleted in the VSV platform that we
describe for Lassa virus. In fact, it has been shown that
mutations truncating the VSV glycoprotein cytoplasmic
domain from 29 to nine or one amino acid are nonpathogenic
in mice [21,39], and, not unexpectedly, there is an absence of
vector-associated pathogenesis in mice receiving vectors with
complete deletion of the VSV glycoprotein [39]. Reassortment
and recombination are other concerns that have been
Figure 5. Cellular Immune Response (IFN-c) in Nonhuman Primates
before Vaccination, after Vaccination, and after Lassa Virus Challenge
Intracellular levels of IFN-c were determined in CD4- and CD8-
positive T-cell populations before vaccination ( 28), after vaccination
( 14 and 0), and after challenge with Lassa virus (7, 14, and 30);
challenge was administered on day 0. Strong cellular responses
following restimulation with transformed cells expressing Lassa GPC
were seen in three of the four animals after challenge. Note: Subjects
1–4 were vaccinated with VSVDG/LVGPC, while controls 1 and 2 were
vaccinated with VSVDG/ZEBOVGP.
DOI: 10.1371/journal.pmed.0020183.g005
Figure 4. Humoral Immune Response in Nonhuman Primates to Lassa
Virus before and after Lassa Challenge
(A) IgG responses were measured using an established ELISA (see
Methods). The titers are presented as endpoint dilutions.
(B) Neutralizing antibodies were detected by a plaque reduction
neutralization assay as described in Methods. Titers are presented as
endpoint dilutions. Note: Subjects 1–4 were vaccinated with VSVDG/
LVGPC, while controls 1 and 2 were vaccinated with VSVDG/
ZEBOVGP.
DOI: 10.1371/journal.pmed.0020183.g004
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Vaccine against Lassa Feverassociated with the use of replication-competent vaccine
platforms. Importantly, the VSV single-stranded RNA genome
does not undergo reassortment and therefore lacks the
potential of reassorting with wild-type viruses in vivo.
Furthermore, VSV replicates within the cytoplasm of infected
cells and does not undergo genetic recombination.
Durability is an important concern and a desirable trait of
any vaccine platform. Indeed, this is an even more important
consideration when developing vaccines against exotic
pathogens such as Lassa virus that exist in remote geographic
locales where boosting is often problematic or not feasible at
all. In these settings, the ideal vaccine would be a single-shot
vaccine capable of providing protection for life or for a very
long period of time. Replication-defective vaccines typically
do not provide such durability. Live viral vaccines have
traditionally offered the most effective long-term protection
against viral infections. Such vaccines tend to induce strong
cellular and humoral host immune responses as a result of the
intracellular synthesis of speciﬁc antigens at high levels over a
prolonged period. Thus, in addition to low seroprevalence in
humans, durability is another important advantage of
exploiting VSV as a vaccine platform. While safety remains
a hurdle that must be overcome before the potential of this
platform can be fully realized, a number of groups are
currently working toward developing the rVSV vaccine
platform for eventual use in humans. Research with rVSV-
based vaccines is underway for HIV, cancer therapy, and
other applications. Notably, the National Institute of Allergy
and Infectious Disease recently awarded a 5-y, 22.8-million
dollar contract to Wyeth to expand research on a candidate
rVSV-based HIV vaccine that was shown to prevent AIDS-like
disease in monkeys [40]. Indeed, the use of replicating rVSV-
based vectors has proven to be a potent and promising
concept for future vaccine development against Lassa fever
and perhaps other lethal viral hemorrhagic fever agents.
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Patient Summary
Background Lassa fever is a disease caused by a virus that is often
spread by rodents. The disease is common in parts of West Africa where
it causes a significant amount of death and disability among the
population. Recently, Lassa fever has been imported by travelers to the
United States and Europe. The Lassa virus that causes the disease is also
on the list of potential bioweapons agents.
Why Was This Study Done? A vaccine against the Lassa virus could help
to control the disease in Africa, protect health workers, and help contain
viral outbreaks. Several groups had developed different vaccines, some
of which could protect monkeys from getting sick. However, none of the
vaccines developed so far have shown all the characteristics one needs
to have before testing them in humans.
What Did the Researchers Do? Many vaccines combine specific parts of
the harmful (pathogenic) virus with other components from harmless
viruses, resulting in an effective but safe vaccine. The researchers
developed a vaccine using a virus called vesicular stomatitis virus as the
harmless component (known as the carrier). They inserted some genetic
material from the harmful Lassa virus. In their study, they gave four
macaque monkeys one shot of this combination vaccine and two others
shots of the ‘‘empty’’ carrier (i.e., just the harmless component).
What Did They Find? When four weeks later they injected all six
monkeys with a lethal dose of Lassa virus, the four monkeys injected
with the combination vaccine stayed healthy. The two monkeys who had
been given just the ‘‘empty’’ carrier died.
What Does This Mean? These are promising early results that justify
further testing of this particular vaccine.
What Next? Issues that need to be resolved before the vaccine can be
tested in humans include the safety of the vesicular stomatitis carrier
virus, how long the vaccine protects after the shot, and whether it is
active against different strains of the Lassa virus (there are at least four
strains, each with slightly different genetic material).
More Information Online Information on Lassa fever can be found at
the following Web sites.
The US CDC Special Pathogens Branch Web site: http://www.cdc.gov/
ncidod/dvrd/spb/
The WHO fact sheet on Lassa Fever (from 2000): http://www.who.int/
mediacentre/factsheets/fs179/en/
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